Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

947.75 +13.61 (+1.46%)
Streaming Delayed Price Updated: 2:28 PM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,435,385
Open 937.00
Bid (Size) 947.47 (2)
Ask (Size) 948.05 (4)
Prev. Close 934.14
Today's Range 936.03 - 950.79
52wk Range 434.34 - 945.69
Shares Outstanding N/A
Dividend Yield 0.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position. 
Via Talk Markets
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate... 
Via Benzinga

Performance

YTD
+60.04%
+60.04%
1 Month
+9.46%
+9.46%
3 Month
+24.77%
+24.77%
6 Month
+49.08%
+49.08%
1 Year
+115.10%
+115.10%

More News

Read More
Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study
Via Investor's Business Daily
In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
Via Benzinga
Eli Lilly Announces CFO Change
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
Should You Buy Eli Lilly Stock After Another Major Win?
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
Via InvestorPlace
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Via Benzinga
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
Via PRLog
Exposures Product Safety
3 Future Blue-Chip Stocks That Could Make You Rich
Via InvestorPlace
Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares
Via The Motley Fool
Topics ETFs
Warren Buffett Recommends This Magnificent Index Fund. It Could Turn $500 Per Month Into $986,900
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
Via Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Via Benzinga
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion – InsideArbitrage
Via AB Newswire
Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
Via InvestorPlace
3 Moonshot Stocks With the Potential to Turn $10K Into $1 Million
Via InvestorPlace
Summer 2024 Snapshot Of The S&P 500's Market Cap
Via Talk Markets
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.